Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(1 year, 3 months from now) |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7550153
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7838027
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7553498
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(3 years from now) | |
US7544370
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(3 years from now) |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8754108
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) | |
US6780881
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) | |
US7351723
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 22 March, 2001
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Market Authorisation Date: 22 October, 1993
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Market Authorisation Date: 24 February, 1998
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic